Experienced in Pudendal Neuralgia

Junqi Q. Niu

71 Xinmin Street, 
Changchun, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Pudendal Neuralgia
71 Xinmin Street, 
Changchun, CN 
OverviewLocationsClinical Research

Overview

Junqi Niu practices in Changchun, China. Niu is rated as an Experienced expert by MediFind in the treatment of Pudendal Neuralgia. Their top areas of expertise are Hepatitis B, Hepatitis, Hepatitis C, and Cirrhosis.

Their clinical research consists of co-authoring 282 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Pudendal Neuralgia.

Locations

71 Xinmin Street, Changchun, 130021, China
Other Locations
NO.1 Jianshe East Road, Zhengzhou, 450052, China
Xinmin Street, Changchun, 130021, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
A Multicenter, Open-label, Phase II Clinical Study to Evaluate the Safety and Efficacy of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B
Enrollment Status: Recruiting
Publish Date: August 26, 2021
Intervention Type: Drug
Study Drugs: APG-1387, Entecavir
Study Phase: Phase 2
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
Enrollment Status: Completed
Publish Date: May 02, 2024
Intervention Type: Drug
Study Drugs: GSK3228836, PegIFN, NA therapy
Study Phase: Phase 2
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment With GSK3228836 in Participants With Chronic Hepatitis B Virus (B-Clear)
Enrollment Status: Completed
Publish Date: May 16, 2023
Intervention Type: Drug
Study Drugs: GSK3228836, Nucleos(t)ide therapy
Study Phase: Phase 2
View 2 Less Clinical Trial

282 Total Publications

Advance in molecular mechanisms underlying diabetes related to viral hepatitis infection.
Advance in molecular mechanisms underlying diabetes related to viral hepatitis infection.
Journal: Frontiers in cellular and infection microbiology
Published: July 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Niu's expertise for a condition
ConditionClose
View All 28 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile